Skip to main content
Top
Published in: Clinical Rheumatology 4/2005

01-08-2005 | Original Article

Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis

Authors: Abdellah El Maghraoui, Saida Tellal, Souad Chaouir, Khalil Lebbar, Ahmed Bezza, Abderrazak Nouijai, Lahsen Achemlal, Sanaa Bouhssain, El Mostapha Derouiche

Published in: Clinical Rheumatology | Issue 4/2005

Login to get access

Abstract

The objective of this study was to determine bone mineral density (BMD) distribution in ankylosing spondylitis (AS) using quantitative computed tomography (QCT), to study bone turnover and anterior pituitary and gonadal hormonal axis in AS, and to look for correlations between BMD, bone remodeling markers and gonadal and anterior pituitary hormones. Forty-three male consecutive patients with AS were enrolled prospectively [mean (SD) age of 36.4 (11.3) years (range: 17–67) and mean disease duration of 6.8 (5.2) years (range: 0.4–19)]. Spine BMD was measured in all patients by QCT, and the results were compared to 29 male patients undergoing lumbar CT scan for sciatica. Bone turnover and anterior pituitary and gonadal axis were assessed in 29 patients, and the results were compared to 30 male healthy blood donors. The mean (SD) BMD was 127.7 mg/cm3 (48.9) (range: 8.8–265.7) and 152.1 (25.3) (range: 34.2–190.4) in patients and controls, respectively (p=0.018). Patients had lower serum levels of osteocalcin and higher levels of serum testosterone, luteinizing hormone (LH), and prolactin than controls with a significant statistical difference. There was a positive significant statistical correlation between BMD and chest expansion, Schober’s test, C7-wall distance, and negative significant statistical correlation with age, disease duration, Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), and serum prolactin. No correlation was observed between bone turnover parameters and AS symptomatic and structural severity indexes. BMD is lower with increasing age and late and severe disease. Decreased bone formation with normal resorption and increased levels of serum prolactin may be involved in its pathophysiology.
Literature
1.
go back to reference Calin A, Taurog J (1998) Spondylarthritides. Oxford University Press, New York, pp 1–347 Calin A, Taurog J (1998) Spondylarthritides. Oxford University Press, New York, pp 1–347
2.
go back to reference van der Linden SJ, van der Heijde D (1998) Ankylosing spondylitis. Rheum Dis Clin North Am 24:663–915PubMed van der Linden SJ, van der Heijde D (1998) Ankylosing spondylitis. Rheum Dis Clin North Am 24:663–915PubMed
3.
go back to reference Yu D (2000) Spondylarthropathies. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology, 6th edn. W.B. Saunders, Philadelphia, pp 1039–1053 Yu D (2000) Spondylarthropathies. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology, 6th edn. W.B. Saunders, Philadelphia, pp 1039–1053
4.
go back to reference Khan MA (ed) (1992) Spondyloarthropathies. W.B. Saunders, Philadelphia Khan MA (ed) (1992) Spondyloarthropathies. W.B. Saunders, Philadelphia
5.
go back to reference El Maghraoui A, Bensabbah R, Bahiri R, Bezza A, Guédira N, Hajjaj-Hassouni N (2003) Cervical spine involvement in ankylosing spondylitis. Clin Rheumatol 22:94–98PubMed El Maghraoui A, Bensabbah R, Bahiri R, Bezza A, Guédira N, Hajjaj-Hassouni N (2003) Cervical spine involvement in ankylosing spondylitis. Clin Rheumatol 22:94–98PubMed
6.
go back to reference El Maghraoui A, Chaouir S, Tabache F, Abouzahir A, Bezza A, Ghafir D, Ohayon V, Archane MI (2003) High resolution thoracic CT in ankylosing spondylitis. Ann Rheum Dis 62:185–186PubMed El Maghraoui A, Chaouir S, Tabache F, Abouzahir A, Bezza A, Ghafir D, Ohayon V, Archane MI (2003) High resolution thoracic CT in ankylosing spondylitis. Ann Rheum Dis 62:185–186PubMed
7.
go back to reference Bezza A, El Maghraoui A, Ghadouane M, Tabache F, Abouzahir A, Abbar M, Ghafir D, Ohayon V, Archane MI (2002) Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report. Joint Bone Spine 69:502–505PubMed Bezza A, El Maghraoui A, Ghadouane M, Tabache F, Abouzahir A, Abbar M, Ghafir D, Ohayon V, Archane MI (2002) Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report. Joint Bone Spine 69:502–505PubMed
8.
go back to reference Will R, Palmer R, Bhalla AK, Ring F, Calin A (1989) Osteoporosis in early ankylosing spondylitis. A primary pathological event? Lancet 2:1483–1485CrossRefPubMed Will R, Palmer R, Bhalla AK, Ring F, Calin A (1989) Osteoporosis in early ankylosing spondylitis. A primary pathological event? Lancet 2:1483–1485CrossRefPubMed
9.
go back to reference Hansen CA, Shagrin JW, Duncan H (1971) Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop 74:59–64PubMed Hansen CA, Shagrin JW, Duncan H (1971) Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop 74:59–64PubMed
10.
go back to reference Raltson SH, Urquhart GDK, Bzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 300:563–565 Raltson SH, Urquhart GDK, Bzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 300:563–565
11.
go back to reference Lee YSL, Schlotzhauer T, Ott SM, van Vollenhoven RF, Hunter J, Shapiro J, Marcus R, McGuire JL (1997) Skeletal status of men with early and late ankylosing spondylitis. Am J Med 103:233–241CrossRefPubMed Lee YSL, Schlotzhauer T, Ott SM, van Vollenhoven RF, Hunter J, Shapiro J, Marcus R, McGuire JL (1997) Skeletal status of men with early and late ankylosing spondylitis. Am J Med 103:233–241CrossRefPubMed
12.
go back to reference Donnelly S, Doyle DV, Denton A, Rolfe J, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMed Donnelly S, Doyle DV, Denton A, Rolfe J, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMed
13.
go back to reference Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMed Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMed
14.
go back to reference Khan MA, Lai J-H, Chang D-M, Liu H-C (1993) Recognizing and managing fractures in ankylosing spondylitis. J Musculoskelet Med 1:45–57 Khan MA, Lai J-H, Chang D-M, Liu H-C (1993) Recognizing and managing fractures in ankylosing spondylitis. J Musculoskelet Med 1:45–57
15.
go back to reference Fox MW, Onofrio BM, Kilgore JE (1993) Neurological complications of ankylosing spondylitis. J Neurosurg 78:871–878PubMed Fox MW, Onofrio BM, Kilgore JE (1993) Neurological complications of ankylosing spondylitis. J Neurosurg 78:871–878PubMed
16.
go back to reference Lehtilen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMed Lehtilen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMed
17.
go back to reference Devogelaer J-P, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum 35:1062–1067PubMed Devogelaer J-P, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum 35:1062–1067PubMed
18.
go back to reference El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Bone Joint Spine 71:573–578 El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Bone Joint Spine 71:573–578
19.
go back to reference Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 4:361–368 Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 4:361–368
20.
go back to reference Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis. The Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 21:1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis. The Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 21:1694–1698PubMed
21.
go back to reference Calin A, Garrett S, Whitelock HC et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock HC et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
22.
go back to reference Garrett SL, Jenkinson T, Kennedy LG, Whitelock HC, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett SL, Jenkinson T, Kennedy LG, Whitelock HC, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
23.
go back to reference Bennet PH, Burch TA (1967) New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 28:453–458 Bennet PH, Burch TA (1967) New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 28:453–458
24.
go back to reference MacKay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27:2866–2872 MacKay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27:2866–2872
25.
go back to reference MacKay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41:2263–2270CrossRefPubMed MacKay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41:2263–2270CrossRefPubMed
26.
go back to reference Lang TF, Li J, Harris ST, Genant HK (1999) Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 23:130–137CrossRefPubMed Lang TF, Li J, Harris ST, Genant HK (1999) Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 23:130–137CrossRefPubMed
27.
go back to reference El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M (1999) Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M (1999) Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed
28.
go back to reference Maillefert JF, Aho S, El Maghraoui A, Dougados M, Roux C (2001) Changes in bone density in patients with ankylosing spondylitis: a two year follow-up study. Osteoporos Int 12:605–609CrossRefPubMed Maillefert JF, Aho S, El Maghraoui A, Dougados M, Roux C (2001) Changes in bone density in patients with ankylosing spondylitis: a two year follow-up study. Osteoporos Int 12:605–609CrossRefPubMed
29.
go back to reference Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roqué M, Larroza M, Munoz-Gomez J (1999) Significant loss of bone mass in patient with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324CrossRefPubMed Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roqué M, Larroza M, Munoz-Gomez J (1999) Significant loss of bone mass in patient with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324CrossRefPubMed
30.
go back to reference Marhoffer W, Stracke H, Masoud H et al (1995) Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 54:556–559PubMed Marhoffer W, Stracke H, Masoud H et al (1995) Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 54:556–559PubMed
31.
go back to reference MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50–53PubMed MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50–53PubMed
32.
go back to reference Brandt J, Frederiksen JK, Jensen CH, Teisner B (2001) The N– and C-telopeptides of human procollagen type I (PINP and PICP): molecular heterogeneity and assay technology. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers. Biochemical and clinical perspectives. Martin Dunitz, London, pp 73–82 Brandt J, Frederiksen JK, Jensen CH, Teisner B (2001) The N– and C-telopeptides of human procollagen type I (PINP and PICP): molecular heterogeneity and assay technology. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers. Biochemical and clinical perspectives. Martin Dunitz, London, pp 73–82
33.
go back to reference Yilmaz N, Ozaslan J (2000) Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 19:92–98PubMed Yilmaz N, Ozaslan J (2000) Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 19:92–98PubMed
34.
go back to reference Gough A, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalized bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMed Gough A, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalized bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMed
35.
go back to reference Laan RFJM, Buijs WCAM, Verbeek ACM et al (1993) Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 52:21–26PubMed Laan RFJM, Buijs WCAM, Verbeek ACM et al (1993) Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 52:21–26PubMed
36.
go back to reference Armour KE, Van’T Hof RJ, Grabowski PS, Reid DM, Ralston SH (1999) Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res 14:2137–2142PubMed Armour KE, Van’T Hof RJ, Grabowski PS, Reid DM, Ralston SH (1999) Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res 14:2137–2142PubMed
37.
go back to reference Szeijfeld VL, Moniier-Faugere MC, Bognar BJ, Ferraz MB, Malluche BJ (1997) Systemic osteopenia and mineralization defect in ankylosing spondylitis. J Rheumatol 24:683–688PubMed Szeijfeld VL, Moniier-Faugere MC, Bognar BJ, Ferraz MB, Malluche BJ (1997) Systemic osteopenia and mineralization defect in ankylosing spondylitis. J Rheumatol 24:683–688PubMed
38.
go back to reference El Maghraoui A, Dougados M, Freneaux E, Chaussade S, Amor B, Breban M (1999) Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. Rheumatology 38:543–546PubMed El Maghraoui A, Dougados M, Freneaux E, Chaussade S, Amor B, Breban M (1999) Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. Rheumatology 38:543–546PubMed
39.
go back to reference Gooren LJ, Giltay EJ, van Schaardenburg D, Dijkmans BA (2000) Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheum Dis Clin North Am 26:969–987PubMed Gooren LJ, Giltay EJ, van Schaardenburg D, Dijkmans BA (2000) Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheum Dis Clin North Am 26:969–987PubMed
40.
go back to reference Mitra D, Elvins DM, Collins AJ (1999) Testosterone and testosterone free index in mild ankylosing spondylitis: relationship with bone mineral density and vertebral fractures. J Rheumatol 26:2414–2417PubMed Mitra D, Elvins DM, Collins AJ (1999) Testosterone and testosterone free index in mild ankylosing spondylitis: relationship with bone mineral density and vertebral fractures. J Rheumatol 26:2414–2417PubMed
41.
go back to reference Straub RH, Struharova S, Scholmerich J, Harle P (2002) No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 20 [6 Suppl 28]:S52–S59PubMed Straub RH, Struharova S, Scholmerich J, Harle P (2002) No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 20 [6 Suppl 28]:S52–S59PubMed
42.
go back to reference Giltay EJ, Popp-Snijders C, van Schaardenburg D, Dekker-Saeys BJ, Gooren LJ, Dijkmans BA (1998) Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J Rheumatol 25:2389–2394PubMed Giltay EJ, Popp-Snijders C, van Schaardenburg D, Dekker-Saeys BJ, Gooren LJ, Dijkmans BA (1998) Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J Rheumatol 25:2389–2394PubMed
43.
go back to reference Giltay EJ, van Schaardenburg D, Gooren LJ, Popp-Snijders C, Dijkmans BA (1999) Androgens and ankylosing spondylitis: a role in the pathogenesis? Ann N Y Acad Sci 876:340–364PubMed Giltay EJ, van Schaardenburg D, Gooren LJ, Popp-Snijders C, Dijkmans BA (1999) Androgens and ankylosing spondylitis: a role in the pathogenesis? Ann N Y Acad Sci 876:340–364PubMed
44.
go back to reference Giltay EJ, Popp-Snijders C, van Denderen JC, van Schaardenburg D, Gooren LJ, Dijkmans BA (2000) Phenylbutazone can spuriously elevate unextracted testosterone assay results in patients with ankylosing spondylitis. J Clin Endocrinol Metab 85:4923–4924 Giltay EJ, Popp-Snijders C, van Denderen JC, van Schaardenburg D, Gooren LJ, Dijkmans BA (2000) Phenylbutazone can spuriously elevate unextracted testosterone assay results in patients with ankylosing spondylitis. J Clin Endocrinol Metab 85:4923–4924
45.
go back to reference Tapia-Serrano R, Jimenez-Balderas FJ, Murrieta S, Bravo-Gatica C, Guerra R, Mintz G (1991) Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol 18:841–848PubMed Tapia-Serrano R, Jimenez-Balderas FJ, Murrieta S, Bravo-Gatica C, Guerra R, Mintz G (1991) Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol 18:841–848PubMed
46.
go back to reference Jara LJ, Silveira LH, Cuellar ML, Pineda CJ, Scopelitis E, Espinoza LR (1994) Hyperprolactinemia in Reiter’s syndrome. J Rheumatol 21:1292–1297PubMed Jara LJ, Silveira LH, Cuellar ML, Pineda CJ, Scopelitis E, Espinoza LR (1994) Hyperprolactinemia in Reiter’s syndrome. J Rheumatol 21:1292–1297PubMed
47.
go back to reference Spangelo BL, Judd AM, Isakson PC, MacLeod RM (1989) Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 125:575–577PubMed Spangelo BL, Judd AM, Isakson PC, MacLeod RM (1989) Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 125:575–577PubMed
48.
go back to reference el Halawani ME, Youngren OM, Silsby JL, Phillips RE (1988) Involvement of serotonin in prolactin release induced by electrical stimulation of the hypothalamus of the turkey (Meleagris gallopavo). Gen Comp Endocrinol 72:323–328PubMed el Halawani ME, Youngren OM, Silsby JL, Phillips RE (1988) Involvement of serotonin in prolactin release induced by electrical stimulation of the hypothalamus of the turkey (Meleagris gallopavo). Gen Comp Endocrinol 72:323–328PubMed
49.
go back to reference Willoughby JO, Menadue MF, Liebelt HJ (1988) Activation of 5-HT 1 serotonin receptors in the medial basal hypothalamus stimulates prolactin secretion in the unanaesthetized rat. Neuroendocrinology 47:83–87PubMed Willoughby JO, Menadue MF, Liebelt HJ (1988) Activation of 5-HT 1 serotonin receptors in the medial basal hypothalamus stimulates prolactin secretion in the unanaesthetized rat. Neuroendocrinology 47:83–87PubMed
50.
go back to reference Pavasuthipaisit K, Norman RL, Spies HG (1980) Evidence that serotonin is involved in prolactin release by electrical stimulation of the medial basal hypothalamus in the rhesus monkey. Neuroendocrinology 31:256–260PubMed Pavasuthipaisit K, Norman RL, Spies HG (1980) Evidence that serotonin is involved in prolactin release by electrical stimulation of the medial basal hypothalamus in the rhesus monkey. Neuroendocrinology 31:256–260PubMed
51.
go back to reference Athreya BH, Rafferty JH, Sehgal GS, Lahita RG (1993) Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 20:725–730PubMed Athreya BH, Rafferty JH, Sehgal GS, Lahita RG (1993) Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 20:725–730PubMed
52.
go back to reference Pauzner R, Urowitz MB, Gladman DD, Gough JM (1994) Prolactin in systemic lupus erythematosus. J Rheumatol 21:2064–2067PubMed Pauzner R, Urowitz MB, Gladman DD, Gough JM (1994) Prolactin in systemic lupus erythematosus. J Rheumatol 21:2064–2067PubMed
53.
go back to reference Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker C, Schneider M (1996) Hyperprolactinemia in systemic lupus erythematosus? Scand J Rheumatol 25:97–102PubMed Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker C, Schneider M (1996) Hyperprolactinemia in systemic lupus erythematosus? Scand J Rheumatol 25:97–102PubMed
54.
go back to reference Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y (1996) No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 23:629–632PubMed Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y (1996) No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 23:629–632PubMed
55.
go back to reference Neidhart M (1996) Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 23:476–481PubMed Neidhart M (1996) Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 23:476–481PubMed
56.
go back to reference Blanco-Favela F, Quintal-Alvarez G, Leanos-Miranda A (1999) Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 26:55–59PubMed Blanco-Favela F, Quintal-Alvarez G, Leanos-Miranda A (1999) Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 26:55–59PubMed
57.
go back to reference McMurray RW, Weidensaul D, Allen SH, Walker SE (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22:2084–2091PubMed McMurray RW, Weidensaul D, Allen SH, Walker SE (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22:2084–2091PubMed
58.
go back to reference Blank M, Krause I, Buskila D et al (1995) Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 162:114–122PubMed Blank M, Krause I, Buskila D et al (1995) Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 162:114–122PubMed
59.
go back to reference Figueroa FE, Carrion F, Martinez ME, Rivero S, Mamani I (1997) Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36:1022–1023PubMed Figueroa FE, Carrion F, Martinez ME, Rivero S, Mamani I (1997) Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36:1022–1023PubMed
60.
go back to reference Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ (1998) Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 7:414–419PubMed Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ (1998) Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 7:414–419PubMed
61.
go back to reference Eulry F, Mayaudon H, Bauduceau B, Lechevalier D, Crozes P, Magnin J, Claude-Berthelot C (1996) Prolactine sérique sous l’effet de la protireline au cours des spondylarthropathies. Essai de traitement de 4 cas d’arthrite réactionnelle et 2 cas de rhumatisme psoriasique par la bromocriptine. Ann Med Interne (Paris) 147:15–19 Eulry F, Mayaudon H, Bauduceau B, Lechevalier D, Crozes P, Magnin J, Claude-Berthelot C (1996) Prolactine sérique sous l’effet de la protireline au cours des spondylarthropathies. Essai de traitement de 4 cas d’arthrite réactionnelle et 2 cas de rhumatisme psoriasique par la bromocriptine. Ann Med Interne (Paris) 147:15–19
Metadata
Title
Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis
Authors
Abdellah El Maghraoui
Saida Tellal
Souad Chaouir
Khalil Lebbar
Ahmed Bezza
Abderrazak Nouijai
Lahsen Achemlal
Sanaa Bouhssain
El Mostapha Derouiche
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1039-8

Other articles of this Issue 4/2005

Clinical Rheumatology 4/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.